When High-Stakes ADC Decisions Can't Wait for More Material or Better Data

Early-stage antibody-drug conjugate (ADC) development often requires critical decisions to be made with limited material and incomplete analytical data. Among the biggest challenges are obtaining accurate concentration and drug-to-antibody ratio (DAR) measurements, particularly when novel linker-payload chemistries alter traditional UV-based calculations. Conventional approaches frequently rely on separate calibration assays or resource-intensive analytical methods that can slow candidate evaluation and consume valuable samples.

A streamlined workflow offers an alternative by combining LC-MRM with a single UV280 measurement to determine linker-payload extinction coefficients while simultaneously establishing ADC concentration. Validated against an orthogonal UV/Vis method, the approach delivers accurate results using minimal material and eliminates the need for separate calibration assays.

Attendees will gain insight into how reliable analytical measurements support developability assessments, improve candidate selection, and create reusable extinction coefficient data that can accelerate characterization across future ADC programs built on the same chemistry.